In one patient, the BRAF mutation was lost during relapse, while the rest of RAS-related genes (KRAS and WT1), and the KMT2A::MLLT3 fusion persisted (Case No. 2), suggesting that the BRAF mutation may not be the driver mutation for this leukemia. This evidence concerns the gene KRAS and leukemia.